Nocturnal acid breakthrough: Clinical significance and management

被引:16
作者
Ang, Tiing Leong [1 ]
Fock, Kwong Ming [1 ]
机构
[1] Changi Gen Hosp, Dept Med, Div Gastroenterol, Singapore 529889, Singapore
关键词
acid breakthrough; proton pump inhibitors;
D O I
10.1111/j.1440-1746.2006.04717.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nocturnal acid breakthrough is seen in more than 70% of Helicobacter pylori-negative patients taking long-term proton pump inhibitors (PPI). It is defined as an intragastric pH of less than 4 for at least 60 consecutive minutes during the overnight period in patients on PPI therapy. It occurs as a result of the recovery of intragastric acidity. Nocturnal acid breakthrough can be clinically significant in patients with complicated gastroesophageal reflux disease, Barrett's esophagus and esophageal motility disorders because of the potential for continued esophageal mucosal injury. To decrease nocturnal acid breakthrough, for patients on once daily PPI, treatment should be stepped up to twice daily. For patients already on twice daily PPI, nocturnal histamine-2 receptor antagonists may be added, but the long-term effectiveness remains debatable as patients may develop tolerance over the course of time. New PPI with a longer half-life may decrease nocturnal acid breakthrough.
引用
收藏
页码:S125 / S128
页数:4
相关论文
共 26 条
[11]   Helicobacter pylori infection influences nocturnal gastric acid breakthrough [J].
Katsube, T ;
Adachi, K ;
Kawamura, A ;
Amano, K ;
Uchida, Y ;
Watanabe, M ;
Kinoshita, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (08) :1049-1056
[12]  
Katz PO, 1998, ALIMENT PHARM THER, V12, P1231
[13]  
Khoury RM, 1999, ALIMENT PHARM THERAP, V13, P675
[14]   Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole [J].
Martínek, J ;
Pantoflicová, D ;
Hucl, T ;
Benes, M ;
Dorta, G ;
Lukás, M ;
Spicák, J .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (05) :445-450
[15]   An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy [J].
Nzeako, UC ;
Murray, JA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (07) :1309-1316
[16]   The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity [J].
Orr, WC ;
Harnish, MJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (12) :1553-1558
[17]   Nocturnal acid breakthrough: Clinical significance and correlation with esophageal acid exposure [J].
Ours, TM ;
Fackler, WK ;
Richter, JE ;
Vaezi, MF .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03) :545-550
[18]   Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects [J].
Peghini, PL ;
Katz, PO ;
Castell, DO .
GASTROENTEROLOGY, 1998, 115 (06) :1335-1339
[19]  
Peghini PL, 1998, AM J GASTROENTEROL, V93, P763
[20]   Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study [J].
Pehlivanov, ND ;
Olyaee, M ;
Sarosiek, I ;
McCallum, RW .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (09) :883-890